Zika Virus Vaccine (DNA-Based) from Japan
Recombinant DNA plasmid Zika vaccine expressing prM-E proteins for neutralizing antibodies. HTS 3002.49.00 for biotechnologically obtained 'other' vaccines. Investigational multi-dose regimen.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Submit Investigational New Drug (IND) documentation
• Classify as finished vaccine product, not gene therapy
• Ensure biotech modification records match heading scope